Printer Friendly

Starting ART following cryptococcal meningitis: the optimal time has yet to be defined.

Patients with cryptococcal meningitis (CM) in Southern Africa present with median [CD4.sup.+] counts <50 cells/[micro]l, [1-4] with a high prevalence of co-morbidities such as tuberculosis (TB) and Kaposi's sarcoma. In this context, the challenge is to balance the competing risks of morbidity and mortality from each additional week of advanced immunosuppression--well demonstrated in South African (SA) HIV cohorts waiting to start antiretroviral therapy (ART) [5]--with those from immune reconstitution inflammatory syndrome (IRIS) occurring within the confined space of the central nervous system, when ART is commenced in the presence of a high fungal antigen load. [6,7]

The first Southern African CM guideline [8] published in 2008 recommended treatment with 1 mg/kg/day amphotericin B for 2 weeks--a regimen known to drive down the cryptococcal burden rapidly in cerebrospinal fluid (CSF), with many patients having sterile CSF by day 14. [1] At this time, given the lack of evidence regarding ART timing in CM, it was recommended to start ART 2-4 weeks after commencing amphotericin B. [8] This window pragmatically coincided with the timing of hospital discharge, and the switch from amphotericin induction therapy to consolidation with fluconazole, with the aim of having asymptomatic patients with sterile or almost-sterile CSF counselled and ready to start ART at outpatient follow-up 4 weeks into antifungal therapy.

Since 2007, two randomised controlled trials (RCTs) of ART timing following CM have been completed in Africa. In the first, conducted by Makadzange et al. [9] in Zimbabwe, patients receiving fluconazole monotherapy for CM were randomised to start ART at [less than or equal to] 72 h v. 10 weeks. [9] The study found excess mortality in the immediate ART arm, most probably due to IRIS, although this information was not collected systematically. [9] Notwithstanding this trial's small sample size and large early loss to follow-up, [10-12] it confirmed the clinical impression that starting ART extremely early was harmful, but it did not provide guidance on what to do in the context of amphotericin-based treatment, nor provide information on ART timing between 3 days and 10 weeks, which represent a far earlier and far later ART-initiation time-point, respectively, than most clinicians would consider in practice.

The Cryptococcal Optimal ART Timing (COAT) trial [13] conducted in Uganda and SA was designed to address these questions, randomising patients treated with amphotericin-based induction (1 mg/kg/day amphotericin B with 800 mg/day fluconazole) to early (1-2 weeks, median 8 days) v. deferred (4-6 weeks, median 36 days) ART. The trial was halted prematurely (N=177 patients randomised) due to excess mortality in the early ART arm, with the most pronounced difference in mortality occurring between days 8 and 30 after CM diagnosis: 21/75 (28%) early ART v. 8/80 (10%) deferred ART (hazard ratio 3.1; p<0.01). This difference occurred despite an apparently similar incidence of CM-IRIS in the two groups (13% v. 10%). [13]

Based on significant differences in mortality in an RCT conducted in an African context following amphotericin treatment, the 2013 Southern African HIV Clinicians Society guidelines committee felt compelled to move the recommended ART start window to 4-6 weeks, in line with the delayed ART group of the COAT trial. This generated some debate among panel members, with some favouring the 4-week time-point.

For all the clear advantages of RCT data, the two ART timing studies do not say anything about a preference between the better-performing study arm and intermediate time-points such as 2, 3 and 4 weeks--they only tell us that the worst-performing arms (i.e. during the first 2 weeks of induction therapy) do not represent the right time to start. Ten weeks was not prioritised over 6 weeks in the Makadzange et al. study, [9] and 5 weeks was not prioritised over 3 or 4 weeks in the COAT trial.

We are unlikely to have any further ART timing RCTs for CM in the near future, given the large cohorts required to power an RCT of ART start at 2 v. 4 weeks post CM treatment. Thus, we may need to edge towards a preferred time based on observational clinical cohort data. In successive SA clinical trial cohorts between 2005 and 2010, [1-4] in which all patients received amphotericin-based induction treatment, with our SA partners we have gradually decreased the median time to ART start from CM diagnosis from 6 weeks [1] to just 23 days (in our latest trial). [4] Despite the concerns of confounding by historic trends in the severity of CM and HIV of patients at presentation, in all four studies [1-41 the median [CD4.sup.+] count was <50 cells/[micro]l, the median baseline fungal burden was high (approximately 5 [log.sub.10] CFU/ml in the CSF), and the percentage of altered mental status--the most significant indicator of poor prognosis in CM--ranged from 13% to 37%, with the latest trial [4] enrolling those with the highest rates.

One-year survival analysis of the combined cohort from the four trials (N=171 patients), who started ART at a median of 31 days (interquartile range 23-46) following a CM diagnosis, showed an earlier flattening of the survival curve in those who started ART within 1 month compared with those who started beyond 1 month. [7] Despite an association of day-14 fungal burden and subsequent CM-IRIS, there was no association of earlier ART initiation and IRIS, and patients who developed IRIS did not have a higher mortality. While CM was the presumed cause of 85% of the deaths in the first 2 weeks, the majority (67%) of deaths after 2 weeks were attributed to other illnesses related to advanced immunosuppression, which might have been prevented through earlier ART initiation.

The absence of RCT evidence favouring the 2-4-week time-points does not translate into evidence against these time-points. Our clinical cohort data and experience in managing HIV patients with CM in the SA setting makes us strong advocates of an ART start time of 4 weeks from CM diagnosis: a time-frame that is being applied in a recently commenced phase III randomised trial of CM treatment at four sites in Africa (ACTA trial, ISRCTN 45035509), and which we believe represents a pragmatic approach based on a synthesis of all available evidence.

References

[1.] Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45(1):76-80.

[2.] Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial. Clin Infect Dis 2008;47(1):123-130. [http://dx.doi. org/10.1086/5887921

[3.] Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012;54(1):121-128. [http://dx.doi. org/10.1093/cid/cir7451

[4.] Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS 2012;26(9):1105-1113. [http://dx.doi.org/10.1097/ QAD.0b013e3283536a931

[5.] Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22(15):1897-1908. [http://dx.doi.org/10.1097/QAD.0b013e32830007cd1

[6.] Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med 2010;7(12):e1000384. [http://dx.doi.org/10.1371/journal.pmed.10003841

[7.] Bicanic T, Jarvis JN, Loyse A, et al. Determinants of acute outcome and long-term survival in HIV-associated cryptococcal meningitis: Results from a combined cohort of 523 patients. Abstract 892. Conference of retroviruses and opportunistic infections (CROI), Boston, USA, 27 February--2 March 2011.

[8.] McCarthy K, Meintjes G, Arthington-Skaggs B, et al. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. Southern African Journal of HIV Medicine 2008;8(3):25-35.

[9.] Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis 2010;50(11):1532-1538. [http:// dx.doi.org/10.1086/6526521

[10.] Bicanic T, Jarvis JN, Muzoora C, Harrison TS. Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis? Clin Infect Dis 2010;51(8):986-987. [http://dx.doi. org/10.1086/6564371

[11.] Boulware DR. Safety, censoring, and intent-to-treat analysis: Dangers to generalizability. Clin Infect Dis 2010;51(8):985-986. [http://dx.doi. org/10.1086/6564361

[12.] Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis 2010;51(8):984-985.

[13.] Boulware DR, Meya D, Muzoora C, et al. ART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: A multisite randomized trial. Abstract 144. Conference on retroviruses and opportunistic infections (CROI), Atlanta, USA, 6 March 2013.

T A Bicanic, (1) MB ChB, MD; J N Jarvis, (1,2) MB ChB, PhD; A Loyse, (1) MB ChB, MD; T S Harrison, (1) MB ChB, MD

(1) Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George's University of London, London, United Kingdom

(2) Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

Corresponding author: T A Bicanic (tbicanic@sgul.ac.uk)
COPYRIGHT 2013 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FORUM
Author:Bicanic, T.A.; Jarvis, J.N.; Loyse, A.; Harrison, T.S.
Publication:Southern African Journal of HIV Medicine
Article Type:Clinical report
Geographic Code:6SOUT
Date:Sep 1, 2013
Words:1612
Previous Article:Message from the executive.
Next Article:Child privacy rights: a 'Cinderella' issue in HIV-prevention research.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters